The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NFκB pathway activation and BCL-XL/BCL-W expression

Nhan Tran, Wendy S. McDonough, Benjamin A. Savitch, Thomas F. Sawyer, Jeffrey A. Winkles, Michael E. Berens

Research output: Contribution to journalArticle

153 Citations (Scopus)

Abstract

The Fn14 gene encodes a type Ia transmembrane protein that belongs to the tumor necrosis factor receptor superfamily. We recently showed that fibroblast growth factor-inducible 14 (Fn14) is overexpressed in migrating glioma cells in vitro and in glioblastoma multiforme clinical specimens in vivo. To determine the biological role of Fn14 in brain cancer progression, we examined the activity of Fn14 as a potential mediator of cell survival. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-stimulated glioma cells had increased cellular resistance to cytotoxic therapy-induced apoptosis. Either TWEAK treatment or Fn14 overexpression in glioma cells resulted in the activation of NFκB and subsequently the translocation of NFκB from the cytoplasm to the nucleus. In addition, Fn14 activation induced BCL-X L and BCL-W mRNA and protein levels, and this effect was dependent upon NFκB transcriptional activity. Substitution of a putative NFκB binding site identified in the BCL-X promoter significantly decreased Fn14-induced transactivation. Furthermore Fn14-induced transactivation of the BCL-X promoter was also diminished by the super-repressor IκBα mutant, which specifically inhibits NFκB activity, and by mutations in the NFκB binding motif of the BCL-X promoter. Additionally small interfering RNA-mediated depletion of either BCL-XL or BCL-W antagonized the TWEAK protective effect on glioma cells. Our results suggest that NFκB-mediated up-regulation of BCL-XL and BCL-W expression in glioma cells increases cellular resistance to cytotoxic therapy-induced apoptosis. We propose that the Fn14 protein functions, in part, through the NFκB signaling pathway to up-regulate BCL-XL and BCL-W expression to foster malignant glioblastoma cell survival. Targeted therapy against Fn14 as an adjuvant to surgery may improve management of invasive glioma cells and advance the outcome of this devastating cancer.

Original languageEnglish (US)
Pages (from-to)3483-3492
Number of pages10
JournalJournal of Biological Chemistry
Volume280
Issue number5
DOIs
StatePublished - Feb 4 2005
Externally publishedYes

Fingerprint

Fibroblast Growth Factors
Glioma
Cell Survival
Tumor Necrosis Factor-alpha
Chemical activation
Cells
Apoptosis
Proteins
Tumor Necrosis Factor Receptors
Glioblastoma
Surgery
Small Interfering RNA
Transcriptional Activation
Brain
Substitution reactions
Up-Regulation
Genes
Binding Sites
Messenger RNA
Biological Factors

ASJC Scopus subject areas

  • Biochemistry

Cite this

The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NFκB pathway activation and BCL-XL/BCL-W expression. / Tran, Nhan; McDonough, Wendy S.; Savitch, Benjamin A.; Sawyer, Thomas F.; Winkles, Jeffrey A.; Berens, Michael E.

In: Journal of Biological Chemistry, Vol. 280, No. 5, 04.02.2005, p. 3483-3492.

Research output: Contribution to journalArticle

@article{b7cafbfd7b524c8382565a5c0e680eee,
title = "The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NFκB pathway activation and BCL-XL/BCL-W expression",
abstract = "The Fn14 gene encodes a type Ia transmembrane protein that belongs to the tumor necrosis factor receptor superfamily. We recently showed that fibroblast growth factor-inducible 14 (Fn14) is overexpressed in migrating glioma cells in vitro and in glioblastoma multiforme clinical specimens in vivo. To determine the biological role of Fn14 in brain cancer progression, we examined the activity of Fn14 as a potential mediator of cell survival. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-stimulated glioma cells had increased cellular resistance to cytotoxic therapy-induced apoptosis. Either TWEAK treatment or Fn14 overexpression in glioma cells resulted in the activation of NFκB and subsequently the translocation of NFκB from the cytoplasm to the nucleus. In addition, Fn14 activation induced BCL-X L and BCL-W mRNA and protein levels, and this effect was dependent upon NFκB transcriptional activity. Substitution of a putative NFκB binding site identified in the BCL-X promoter significantly decreased Fn14-induced transactivation. Furthermore Fn14-induced transactivation of the BCL-X promoter was also diminished by the super-repressor IκBα mutant, which specifically inhibits NFκB activity, and by mutations in the NFκB binding motif of the BCL-X promoter. Additionally small interfering RNA-mediated depletion of either BCL-XL or BCL-W antagonized the TWEAK protective effect on glioma cells. Our results suggest that NFκB-mediated up-regulation of BCL-XL and BCL-W expression in glioma cells increases cellular resistance to cytotoxic therapy-induced apoptosis. We propose that the Fn14 protein functions, in part, through the NFκB signaling pathway to up-regulate BCL-XL and BCL-W expression to foster malignant glioblastoma cell survival. Targeted therapy against Fn14 as an adjuvant to surgery may improve management of invasive glioma cells and advance the outcome of this devastating cancer.",
author = "Nhan Tran and McDonough, {Wendy S.} and Savitch, {Benjamin A.} and Sawyer, {Thomas F.} and Winkles, {Jeffrey A.} and Berens, {Michael E.}",
year = "2005",
month = "2",
day = "4",
doi = "10.1074/jbc.M409906200",
language = "English (US)",
volume = "280",
pages = "3483--3492",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "5",

}

TY - JOUR

T1 - The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NFκB pathway activation and BCL-XL/BCL-W expression

AU - Tran, Nhan

AU - McDonough, Wendy S.

AU - Savitch, Benjamin A.

AU - Sawyer, Thomas F.

AU - Winkles, Jeffrey A.

AU - Berens, Michael E.

PY - 2005/2/4

Y1 - 2005/2/4

N2 - The Fn14 gene encodes a type Ia transmembrane protein that belongs to the tumor necrosis factor receptor superfamily. We recently showed that fibroblast growth factor-inducible 14 (Fn14) is overexpressed in migrating glioma cells in vitro and in glioblastoma multiforme clinical specimens in vivo. To determine the biological role of Fn14 in brain cancer progression, we examined the activity of Fn14 as a potential mediator of cell survival. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-stimulated glioma cells had increased cellular resistance to cytotoxic therapy-induced apoptosis. Either TWEAK treatment or Fn14 overexpression in glioma cells resulted in the activation of NFκB and subsequently the translocation of NFκB from the cytoplasm to the nucleus. In addition, Fn14 activation induced BCL-X L and BCL-W mRNA and protein levels, and this effect was dependent upon NFκB transcriptional activity. Substitution of a putative NFκB binding site identified in the BCL-X promoter significantly decreased Fn14-induced transactivation. Furthermore Fn14-induced transactivation of the BCL-X promoter was also diminished by the super-repressor IκBα mutant, which specifically inhibits NFκB activity, and by mutations in the NFκB binding motif of the BCL-X promoter. Additionally small interfering RNA-mediated depletion of either BCL-XL or BCL-W antagonized the TWEAK protective effect on glioma cells. Our results suggest that NFκB-mediated up-regulation of BCL-XL and BCL-W expression in glioma cells increases cellular resistance to cytotoxic therapy-induced apoptosis. We propose that the Fn14 protein functions, in part, through the NFκB signaling pathway to up-regulate BCL-XL and BCL-W expression to foster malignant glioblastoma cell survival. Targeted therapy against Fn14 as an adjuvant to surgery may improve management of invasive glioma cells and advance the outcome of this devastating cancer.

AB - The Fn14 gene encodes a type Ia transmembrane protein that belongs to the tumor necrosis factor receptor superfamily. We recently showed that fibroblast growth factor-inducible 14 (Fn14) is overexpressed in migrating glioma cells in vitro and in glioblastoma multiforme clinical specimens in vivo. To determine the biological role of Fn14 in brain cancer progression, we examined the activity of Fn14 as a potential mediator of cell survival. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-stimulated glioma cells had increased cellular resistance to cytotoxic therapy-induced apoptosis. Either TWEAK treatment or Fn14 overexpression in glioma cells resulted in the activation of NFκB and subsequently the translocation of NFκB from the cytoplasm to the nucleus. In addition, Fn14 activation induced BCL-X L and BCL-W mRNA and protein levels, and this effect was dependent upon NFκB transcriptional activity. Substitution of a putative NFκB binding site identified in the BCL-X promoter significantly decreased Fn14-induced transactivation. Furthermore Fn14-induced transactivation of the BCL-X promoter was also diminished by the super-repressor IκBα mutant, which specifically inhibits NFκB activity, and by mutations in the NFκB binding motif of the BCL-X promoter. Additionally small interfering RNA-mediated depletion of either BCL-XL or BCL-W antagonized the TWEAK protective effect on glioma cells. Our results suggest that NFκB-mediated up-regulation of BCL-XL and BCL-W expression in glioma cells increases cellular resistance to cytotoxic therapy-induced apoptosis. We propose that the Fn14 protein functions, in part, through the NFκB signaling pathway to up-regulate BCL-XL and BCL-W expression to foster malignant glioblastoma cell survival. Targeted therapy against Fn14 as an adjuvant to surgery may improve management of invasive glioma cells and advance the outcome of this devastating cancer.

UR - http://www.scopus.com/inward/record.url?scp=13544268326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13544268326&partnerID=8YFLogxK

U2 - 10.1074/jbc.M409906200

DO - 10.1074/jbc.M409906200

M3 - Article

C2 - 15611130

AN - SCOPUS:13544268326

VL - 280

SP - 3483

EP - 3492

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 5

ER -